Compounds > 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine
Page last updated: 2024-11-08

3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine: amiloride prodrug; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID194530
CHEMBL ID290169
SCHEMBL ID11053565
MeSH IDM0085707

Synonyms (14)

Synonym
cgs 4270
73631-29-5
CHEMBL290169 ,
3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloropyrazine-2,6-diamine
cgs-4270
unii-pf467u2v7j
3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole
pf467u2v7j ,
2,6-pyrazinediamine, 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-
3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine
bdbm50356116
DTXSID90223847
SCHEMBL11053565
FT-0743072
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Urokinase-type plasminogen activatorHomo sapiens (human)IC50 (µMol)1,000.00000.03703.385910.0000AID626488
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (21)

Processvia Protein(s)Taxonomy
positive regulation of cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaUrokinase-type plasminogen activatorHomo sapiens (human)
proteolysisUrokinase-type plasminogen activatorHomo sapiens (human)
chemotaxisUrokinase-type plasminogen activatorHomo sapiens (human)
signal transductionUrokinase-type plasminogen activatorHomo sapiens (human)
blood coagulationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of signaling receptor activityUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesion mediated by integrinUrokinase-type plasminogen activatorHomo sapiens (human)
urokinase plasminogen activator signaling pathwayUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell population proliferationUrokinase-type plasminogen activatorHomo sapiens (human)
fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of wound healingUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityUrokinase-type plasminogen activatorHomo sapiens (human)
protein bindingUrokinase-type plasminogen activatorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
extracellular regionUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
focal adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
external side of plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
cell surfaceUrokinase-type plasminogen activatorHomo sapiens (human)
specific granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular exosomeUrokinase-type plasminogen activatorHomo sapiens (human)
tertiary granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexUrokinase-type plasminogen activatorHomo sapiens (human)
protein complex involved in cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase complexUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (47)

Assay IDTitleYearJournalArticle
AID18959Compound was tested for diuretic activity against peroral dose of 50 mg/kg in rat1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Synthesis and diuretic profile of 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine, an amiloride-type diuretic.
AID18962Compound was tested for diuretic activity in urine volume in dogs at a dose of 5 mg/kg1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Synthesis and diuretic profile of 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine, an amiloride-type diuretic.
AID16171Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Synthesis and diuretic profile of 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine, an amiloride-type diuretic.
AID62812Compound was evaluated for urinary levels (mg) after administration of 0.1 mg/kg at time period 0-24 hr1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175981Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (K+) at a time period of 0-5 hr for dose 9 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175987Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Na+) at a time period of 0-5 hr for dose 3 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175826Compound was evaluated for diuretic activity determined by the ability of to induce electrolytic excretion (Cl-) at a time period of 0-24 hr for dose 3 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID18956Compound was tested for diuretic activity against peroral dose of 100 mg/kg in rat1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Synthesis and diuretic profile of 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine, an amiloride-type diuretic.
AID16009Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Synthesis and diuretic profile of 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine, an amiloride-type diuretic.
AID175829Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Cl-) at a time period of 0-24 hr for dose 81 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175986Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Na+) at a time period of 0-5 hr for dose 27 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175979Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (K+) at a time period of 0-5 hr for dose 3 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175976Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (K+) at a time period of 0-24 hr for dose 81 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175985Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Na+) at a time period of 0-24 hr for dose 9 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID18958Compound was tested for diuretic activity against peroral dose of 25 mg/kg in rat1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Synthesis and diuretic profile of 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine, an amiloride-type diuretic.
AID175831Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Cl-) at a time period of 0-5 hr for dose 27 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID16008Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Synthesis and diuretic profile of 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine, an amiloride-type diuretic.
AID626488Inhibition of urokinase-type plasminogen activator2011Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22
Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA).
AID175832Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Cl-) at a time period of 0-5 hr for dose 3 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID58592Diuretic activity in mongrel dog was determined by the ability to induce electrolytic excretion (Na+) at a time period of 0-5 hr after administration of 4 mg/kg dose.1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID191506Urine volumes in Sprague-Dawley rats was determined at time period of 0-5 hours dose 3 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175827Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Cl-) at a time period of 0-24 hr for dose 27 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID62813Compound was evaluated for urinary levels (mg) after administration of 0.1 mg/kg at time period 0-6 hr1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175983Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Na+) at a time period of 0-24 hr for dose 3 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175978Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (K+) at a time period of 0-5 hr for dose 27 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID58591Diuretic activity in mongrel dog was determined by the ability to induce electrolytic excretion (K+) at a time period of 0-5 hr after administration of 4 mg/kg dose.1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID18957Compound was tested for diuretic activity against peroral dose of 10 mg/kg in rat1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Synthesis and diuretic profile of 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine, an amiloride-type diuretic.
AID18960Compound was tested for diuretic activity against peroral dose of 5 mg/kg in rat1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Synthesis and diuretic profile of 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine, an amiloride-type diuretic.
AID16170Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Synthesis and diuretic profile of 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine, an amiloride-type diuretic.
AID175984Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Na+) at a time period of 0-24 hr for dose 81 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175975Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (K+) at a time period of 0-24 hr for dose 3 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID62814Compound was evaluated for urinary levels (mg) after administration of 0.1 mg/kg at time period 6-24h1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID58404Compound was evaluated for percentage recovery from urine after administration of 0.1 mg/kg dose1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175834Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Cl-) at a time period of 0-5 hr for dose 9 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID58405Compound was evaluated for percentage recovery from urine after administration of 0.3 mg/kg dose1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175988Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Na+) at a time period of 0-5 hr for dose 81 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175989Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Na+) at a time period of 0-5 hr for dose 9 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID58590Diuretic activity in mongrel dog was determined by the ability to induce electrolytic excretion (CL-) at a time period of 0-5 hr after administration of 4 mg/kg dose.1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175835Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (K+) at a time period of 0-24 hr for dose 27 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175980Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (K+) at a time period of 0-5 hr for dose 81 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID191508Urine volumes in Sprague-Dawley rats was determined at time period of 0-5 hours dose 9 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175830Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Cl-) at a time period of 0-24 hr for dose 9 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID191507Urine volumes in Sprague-Dawley rats was determined at time period of 0-5 hours dose 81 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID191505Urine volumes in Sprague-Dawley rats was determined at time period of 0-5 hours dose 27 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175977Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (K+) at a time period of 0-24 hr for dose 9 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175833Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Cl-) at a time period of 0-5 hr for dose 81 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175982Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Na+) at a time period of 0-24 hr for dose 27 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (80.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.53 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorine
chloride : A halide anion formed when chlorine picks up an electron to form an an anion.		1.9610halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
hydrochlorothiazide
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.		1.9510benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
benzimidazole
1H-benzimidazole : The 1H-tautomer of benzimidazole.		1.9610benzimidazole;
polycyclic heteroarene
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		2.8840diazine;
pyrazines		Daphnia magna metabolite
amiloride
Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.		2.6530aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker
amiloride hydrochloride
amiloride hydrochloride dihydrate : A hydrate that is the dihydrate of amiloride hydrochloride.		2.3920hydratediuretic;
sodium channel blocker
quinidine
Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.		1.9610cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
quinine
[no description available]		1.9610cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
oxadiazoles
Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.		2.3620
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		02.0610
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0610